Sameh ElFangary, Country President for GCC and Pakistan at AstraZeneca, highlights AstraZeneca’s alignment with, and commitment to, Saudi Arabia’s Vision 2030 and the opportunities that the Vision is creating. ElFangary also explains the significance of a new memorandum of understanding to create a clinical research hub in Riyadh and how the COVID-19 experience has underlined the Anglo-Swedish drug maker’s commitment to patients.
The world around us is changing and the burden of disease is increasing. We are responding by increasing our focus on growth through innovation - being more patient-centric, doing more with technology, digital and data, and advancing more cutting-edge science
